华蟾素注射液多肽成分体外抗肿瘤活性研究

被引：43

作者：

吴旭 ^{[1
]}

高波 ^{[2
]}

杨健 ^{[1
]}

边宝林 ^{[1
]}

王宏洁 ^{[1
]}

机构：

[1] 中国中医科学院中药研究所

[2] 安徽金蟾生化股份有限公司

来源：

药学学报 | 2012年 / 06期

关键词：

华蟾素注射液; 多肽组分; 抗肿瘤; 抑制增殖;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100706 [药理学];

摘要：

<正>华蟾素是从中华大蟾蜍Bufo bufo gargarizansCantor的干燥皮提取精制而成的水溶性制剂,已列为国家中药保护品种。其注射液是应用较早的剂型之一,目前广泛应用于多种中晚期肿瘤,如原发性肝癌、胃癌、肺癌、结肠癌、胰腺癌等[1?3]。大量的临床与实验研究证实华蟾素注射液是安全、有效的抗

引用

页码：822 / 826

页数：5

共 6 条

[1]

Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma[J] Tian-Jie Qin; Xin-Han Zhao; Ling-Xiao Zhang; Zhi-Ping Ruan; Department of Medical Oncology; First Affiliated Hospital of Medical School of Xi’an Jiaotong University; Xi’an 710061; Shaanxi Province; China Bo-Rong Pan; Outpatient Department of Oncology; Cancer Institute; Fourth Military Medical University; Xi’an 710032; Shaanxi Province; China Jun Yun; Department of the Third G

[2]

Apoptosis-inducing activity of compounds screened and characterizedfrom cinobufacini by bioassay-guided isolation[J] Dong-Liang Wang;Fang-Hua Qi;Huan-Li Xu;Yoshinori Inagaki;Yutaka Orihara;Kazuhisa Sekimizu;Norihiro Kokudo;Feng-Shan Wang;Wei Tang Molecular Medicine Reports 2010,

[3]

Pilot study of huachansu in patients with hepatocellular carcinoma; nonsmall‐cell lung cancer; or pancreatic cancer[J] ZhiqiangMeng;PeiyingYang;YehuaShen;WenyingBei;YingZhang;YongqianGe;Robert A.Newman;LorenzoCohen;LumingLiu;BobThornton;David Z.Chang;ZongxingLiao;RazelleKurzrock Cancer 2009,

[4]

Involvement of Caspase-3 Activity and Survivin Downregulation inCinobufocini-Induced Apoptosis in A 549 Cells[J] Juyong Wang;Ye Jin;Zhenye Xu;Zhan Zheng;Su Wan Experimental Biology and Medicine 2009,

[5]

Host defense peptides as new weapons in cancer treatment[J] N. Papo;Y. Shai CMLS Cellular and Molecular Life Sciences 2005,

[6]

A Novel Antimicrobial Peptide from Bufo bufo gargarizans[J] Chan Bae Park;Mi Sun Kim;Sun Chang Kim Biochemical and Biophysical Research Communications 1996,

← 1 →